Christian Cornelissen

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

Journal: Journal of medical Internet research

Published: January 22, 2020

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.

Journal: Journal of neurology

Published: January 18, 2020

Differentiating societal costs of disability worsening in multiple sclerosis.

Differentiating societal costs of disability worsening in multiple sclerosis.

Journal: Journal of neurology

Published: October 21, 2019

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

Journal: Multiple sclerosis and related disorders

Published: July 29, 2019

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 27, 2018

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: December 24, 2017

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.

Journal: PloS one

Published: August 25, 2016

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.

Journal: BMC neurology

Published: February 11, 2016

The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.

The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.

Journal: BMC neurology

Published: April 07, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026